12
Participants
Start Date
October 1, 2010
Primary Completion Date
April 12, 2012
Study Completion Date
January 16, 2014
SB939
"Dose Levels for Part A~-1 - 20mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~1. (starting dose) 25mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~2. \- 35mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~3. \- 45mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~4+ - Previous level + 10mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing"
Alberta Children's Hospital, Calgary
Stollery Children's Hospital, Edmonton
Children's and Women's Health Centre of BC Branch, Vancouver
CancerCare Manitoba, Winnipeg
Izaak Walton Killam (IWK) Health Centre, Halifax
Children's Hospital of Eastern Ontario, Ottawa
Hospital for Sick Children, Toronto
CHU Sainte-Justine, Montreal
Lead Sponsor
S*BIO
INDUSTRY
NCIC Clinical Trials Group
NETWORK